Q-omics provides the consensus-scored ZBTB40-IT1 profile across patient tissues and cancer cell-line models. ZBTB40-IT1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZBTB40-IT1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ZBTB40-IT1 RNA expression shows 17,526 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where ZBTB40-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB40-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB40-IT1 survival associations across molecular data types. ZBTB40-IT1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB40-IT1 RNA expression–survival associations across cancer types. High ZBTB40-IT1 expression shows unfavorable associations in ACC, COAD and STAD, but favorable associations in LUAD, BRCA and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for ZBTB40-IT1 RNA expression.
This table summarizes ZBTB40-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB40-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB40-IT1 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, COAD, LIHC and BLCA. The KIRC box plot shows higher ZBTB40-IT1 RNA expression in tumor versus normal tissue (log2 FC = +0.305, t-test p < 0.001).
This table shows molecular features associated with ZBTB40-IT1 in patient tissues and cancer cell lines. In patient samples, ZBTB40-IT1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
